Argos Therapeutics (ARGS) Files $60M IPO

December 31, 2013 11:21 AM EST
Argos Therapeutics, Inc. (Nasdaq: ARGS) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $60 million. The company plans to list on the Nasdaq Global Market under the ticker, ARGS.

The offering is being made via Piper Jaffray, Stifel, JMP Securities, and Needham & Company.

Argos Therapeutics a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on our proprietary technology platform called Arcelis.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Piper Jaffray, Needham & Company, JMP Securities, IPO

Add Your Comment